Medaysis
Enable Innovation

DATA SHEET

Mouse Anti-Vimentin [LN-6]: MC0965, MC0965RTU7

Intended Use: For Research Use Only

Description: Anti-vimentin is of limited value as a diagnostic tool; however, when used in combination with other antibodies (in panels) it is useful for the subclassification of a given tumor. Expression of vimentin, when used in conjunction with anti-keratin, is helpful when distinguishing melanomas from undifferentiated carcinomas and large cell lymphomas. All melanomas and Schwannomas react strongly with anti-vimentin. This antibody recognizes a 57 kD intermediate filament. It labels a variety of mesenchymal cells, including melanocytes, lymphocytes, endothelial cells, and fibroblasts. Non-reactivity of anti-vimentin is often considered more useful than its positive reactivity, since there are a few tumors that do not contain vimentin, e.g. hepatoma and seminoma. Anti-vimentin is also useful as a tissue process control reagent.

Specifications

Clone:	LN-6
Source:	Mouse
Isotype:	IgM
Reactivity:	Human, cat, cow, pig, rat, rabbit, mouse, sheep
Localization:	Cytoplasm
Formulation:	Antibody in PBS pH7.4, containing BSA and ≤ 0.09% sodium azide (NaN3)
Storage:	Store at 2°- 8°C
Applications:	IHC, Flow Cyt., ICC/IF

Package:

Description	Catalog No.	Size
Vimentin Concentrated	MC0965	1 ml
Vimentin Prediluted	MC0965RTU7	7 ml

IHC Procedure

Positive Control Tissue:	Tonsil
Concentrated Dilution:	50-200
Pretreatment:	Citrate pH6.0 or EDTA pH8.0, 15 minutes using Pressure Cooker, or 30-60 minutes using water bath at 95°-99°C
Incubation Time and Temp:	30-60 minutes @ RT
Detection:	Refer to the detection system manual

* Result should be confirmed by an established diagnostic procedure.



FFPE human Melanoma stained with Vimentin (LN-6)

References:

1. Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer. Takai K, et al. Oncotarget 7:82889-82901, 2016.
2. miR-34 activity is modulated through 5'-end phosphorylation in response to DNA damage. Salzman DW, et al. Nat Commun 7:10954, 2016.
3. Effects of ranibizumab on TGF-ß1 and TGF-ß2 production by human Tenon's fibroblasts: Noh SM, et al. An in vitro study. Mol Vis 21:1191-200, 2015.

Orders: customercare@medaysis.com Support: techsupport@medaysis.com Tel: 510-509-3153 www.medaysis.com